Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daphné Benteyn

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Methods in Molecular Biology (Clifton, N.J.)|May 30, 2016
Engineering WT1-Encoding mRNA to Increase Translational Efficiency in Dendritic CellsDaphné Benteyn, Carlo Heirman, Kris Thielemans, et al.
Expert Review of Vaccines|September 9, 2014
mRNA-based dendritic cell vaccinesDaphné Benteyn, Carlo Heirman, Aude Bonehill, et al.
World Journal of Gastroenterology|January 13, 2016
Current status and perspectives of immune-based therapies for hepatocellular carcinomaMaridi Aerts, Daphné Benteyn, Hans Van Vlierberghe, et al.
Methods in Molecular Biology (Clifton, N.J.)|March 13, 2014
Single-step antigen loading and maturation of dendritic cells through mRNA electroporation of a tumor-associated antigen and a TriMix of costimulatory moleculesDaphné Benteyn, An M T Van Nuffel, Sofie Wilgenhof, et al.
Biomed Research International|March 20, 2013
Characterization of CD8+ T-cell responses in the peripheral blood and skin injection sites of melanoma patients treated with mRNA electroporated autologous dendritic cells (TriMixDC-MEL)Daphné Benteyn, An M T Van Nuffel, Sofie Wilgenhof, et al.
Cancer Immunology, Immunotherapy : CII|December 14, 2011
Intravenous and intradermal TriMix-dendritic cell therapy results in a broad T-cell response and durable tumor response in a chemorefractory stage IV-M1c melanoma patientAn M T Van Nuffel, Daphné Benteyn, Sofie Wilgenhof, et al.
Cancer Immunology, Immunotherapy : CII|December 31, 2014
Long-term clinical outcome of melanoma patients treated with messenger RNA-electroporated dendritic cell therapy following complete resection of metastasesSofie Wilgenhof, Jurgen Corthals, An M T Van Nuffel, et al.
Cancer Immunology, Immunotherapy : CII|April 22, 2016
Disease progression in recurrent glioblastoma patients treated with the VEGFR inhibitor axitinib is associated with increased regulatory T cell numbers and T cell exhaustionStephanie Du Four, Sarah K Maenhout, Daphné Benteyn, et al.
Journal of Immunological Methods|January 25, 2012
Epitope and HLA-type independent monitoring of antigen-specific T-cells after treatment with dendritic cells presenting full-length tumor antigensAn M T Van Nuffel, Sandra Tuyaerts, Daphné Benteyn, et al.
Cancer Research|February 17, 2012
Preclinical evaluation of TriMix and antigen mRNA-based antitumor therapySandra Van Lint, Cleo Goyvaerts, Sarah Maenhout, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Methods in Molecular Biology (Clifton, N.J.)|May 30, 2016
Engineering WT1-Encoding mRNA to Increase Translational Efficiency in Dendritic CellsDaphné Benteyn, Carlo Heirman, Kris Thielemans, et al.
Expert Review of Vaccines|September 9, 2014
mRNA-based dendritic cell vaccinesDaphné Benteyn, Carlo Heirman, Aude Bonehill, et al.
World Journal of Gastroenterology|January 13, 2016
Current status and perspectives of immune-based therapies for hepatocellular carcinomaMaridi Aerts, Daphné Benteyn, Hans Van Vlierberghe, et al.
Methods in Molecular Biology (Clifton, N.J.)|March 13, 2014
Single-step antigen loading and maturation of dendritic cells through mRNA electroporation of a tumor-associated antigen and a TriMix of costimulatory moleculesDaphné Benteyn, An M T Van Nuffel, Sofie Wilgenhof, et al.
Biomed Research International|March 20, 2013
Characterization of CD8+ T-cell responses in the peripheral blood and skin injection sites of melanoma patients treated with mRNA electroporated autologous dendritic cells (TriMixDC-MEL)Daphné Benteyn, An M T Van Nuffel, Sofie Wilgenhof, et al.
Cancer Immunology, Immunotherapy : CII|December 14, 2011
Intravenous and intradermal TriMix-dendritic cell therapy results in a broad T-cell response and durable tumor response in a chemorefractory stage IV-M1c melanoma patientAn M T Van Nuffel, Daphné Benteyn, Sofie Wilgenhof, et al.
Cancer Immunology, Immunotherapy : CII|December 31, 2014
Long-term clinical outcome of melanoma patients treated with messenger RNA-electroporated dendritic cell therapy following complete resection of metastasesSofie Wilgenhof, Jurgen Corthals, An M T Van Nuffel, et al.
Cancer Immunology, Immunotherapy : CII|April 22, 2016
Disease progression in recurrent glioblastoma patients treated with the VEGFR inhibitor axitinib is associated with increased regulatory T cell numbers and T cell exhaustionStephanie Du Four, Sarah K Maenhout, Daphné Benteyn, et al.
Journal of Immunological Methods|January 25, 2012
Epitope and HLA-type independent monitoring of antigen-specific T-cells after treatment with dendritic cells presenting full-length tumor antigensAn M T Van Nuffel, Sandra Tuyaerts, Daphné Benteyn, et al.
Cancer Research|February 17, 2012
Preclinical evaluation of TriMix and antigen mRNA-based antitumor therapySandra Van Lint, Cleo Goyvaerts, Sarah Maenhout, et al.
Pageof 2